SG11202008247WA - Matrix metalloproteinase-1 antisense oligonucleotides - Google Patents

Matrix metalloproteinase-1 antisense oligonucleotides

Info

Publication number
SG11202008247WA
SG11202008247WA SG11202008247WA SG11202008247WA SG11202008247WA SG 11202008247W A SG11202008247W A SG 11202008247WA SG 11202008247W A SG11202008247W A SG 11202008247WA SG 11202008247W A SG11202008247W A SG 11202008247WA SG 11202008247W A SG11202008247W A SG 11202008247WA
Authority
SG
Singapore
Prior art keywords
antisense oligonucleotides
matrix metalloproteinase
metalloproteinase
matrix
antisense
Prior art date
Application number
SG11202008247WA
Other languages
English (en)
Inventor
Seon-Young Han
Kiho Sung
Myunghyo Hong
Youree Oh
Jeong-Seok Heo
Kang Won Jang
Original Assignee
Olipass Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olipass Corp filed Critical Olipass Corp
Publication of SG11202008247WA publication Critical patent/SG11202008247WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
SG11202008247WA 2018-05-18 2019-05-03 Matrix metalloproteinase-1 antisense oligonucleotides SG11202008247WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180057352 2018-05-18
PCT/KR2019/005994 WO2019221570A1 (en) 2018-05-18 2019-05-03 Matrix metalloproteinase-1 antisense oligonucleotides

Publications (1)

Publication Number Publication Date
SG11202008247WA true SG11202008247WA (en) 2020-12-30

Family

ID=68540475

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008247WA SG11202008247WA (en) 2018-05-18 2019-05-03 Matrix metalloproteinase-1 antisense oligonucleotides

Country Status (13)

Country Link
US (1) US20210292369A1 (ja)
EP (1) EP3794124A4 (ja)
JP (1) JP7422406B2 (ja)
KR (1) KR102194594B1 (ja)
CN (1) CN112041447B (ja)
AR (1) AR114533A1 (ja)
AU (1) AU2019268955A1 (ja)
BR (1) BR112020017892A2 (ja)
CA (1) CA3091911A1 (ja)
MX (1) MX2020009836A (ja)
SG (1) SG11202008247WA (ja)
TW (1) TWI832851B (ja)
WO (1) WO2019221570A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102304280B1 (ko) 2018-08-14 2021-09-23 올리패스 주식회사 아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719262A (en) * 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US6617422B1 (en) * 1997-05-23 2003-09-09 Peter Nielsen Peptide nucleic acid monomers and oligomers
US20030105044A1 (en) * 2001-10-17 2003-06-05 Isis Pharmaceuticals Inc. Antisense modulation of matrix metalloproteinase 1 expression
AU2001250572A1 (en) * 2000-04-07 2001-10-23 Epigenomics Ag Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
DE10238298A1 (de) * 2002-08-21 2004-03-04 Beiersdorf Ag Verwendung von Antisense-Oligonucleotiden zur Behandlung von degenerativen Hauterscheinungen
WO2005030787A2 (en) * 2003-09-29 2005-04-07 Topigen Pharmaceutique Inc. Oligonucleotide compositions and methods for treating disease including inflammatory conditions
US7511025B2 (en) * 2004-06-16 2009-03-31 Trustees Of Dartmouth College Compositions and methods for inhibiting the synthesis or expression of MMP-1
KR20090098710A (ko) * 2008-03-14 2009-09-17 주식회사 씨티아이바이오 세포투과성과 핵산 결합력이 좋은 펩타이드 핵산 유도체
KR20120073536A (ko) * 2010-12-27 2012-07-05 주식회사 파나진 다중전하를 갖는 ｐｎａ
US20150240239A1 (en) * 2014-02-27 2015-08-27 Nugen Biosience (Taiwan) Co., Ltd. Methods and pharmaceutical compositions for inhibiting matrix metalloproteinases 1 by interference ribonucleic acid
CN107073294A (zh) * 2014-09-05 2017-08-18 阿克赛医药公司 使用靶向tyr或mmp1的核酸治疗老化和皮肤病症的方法
EP3497114B1 (en) * 2016-08-08 2024-10-16 Olipass Corporation Androgen receptor antisense oligonucleotides
JP6997177B2 (ja) * 2016-09-16 2022-02-04 オリパス コーポレーション Ｓｃｎ９ａアンチセンスオリゴヌクレオチド
EP3526239B1 (en) * 2016-10-11 2021-11-03 Olipass Corporation Hif 1-alpha antisense oligonucleotides
CA3046904A1 (en) * 2016-12-30 2018-07-05 Olipass Corporation Exon skipping by peptide nucleic acid derivatives

Also Published As

Publication number Publication date
JP7422406B2 (ja) 2024-01-26
AU2019268955A1 (en) 2020-11-26
TW202002991A (zh) 2020-01-16
WO2019221570A1 (en) 2019-11-21
KR20190132220A (ko) 2019-11-27
CN112041447B (zh) 2024-09-13
KR102194594B1 (ko) 2020-12-23
CA3091911A1 (en) 2019-11-21
TWI832851B (zh) 2024-02-21
EP3794124A4 (en) 2022-08-10
JP2021524236A (ja) 2021-09-13
CN112041447A (zh) 2020-12-04
EP3794124A1 (en) 2021-03-24
US20210292369A1 (en) 2021-09-23
AR114533A1 (es) 2020-09-16
BR112020017892A2 (pt) 2020-12-22
MX2020009836A (es) 2021-01-08

Similar Documents

Publication Publication Date Title
IL276549A (en) CAMK2D antisense oligonucleotides and their uses
GB201904709D0 (en) Chemically modified oligonucleotides
IL268422A (en) Targeted oligonucleotides
IL281834A (en) Dilution of RNA using nuclease
GB201711809D0 (en) Antisense oligonucleotide
IL257091B (en) Targeted oligonucleotides
IL275950A (en) Antisense alpha-synuclein oligonucleotides and their use
IL280724A (en) Chemically modified oligonucleotides directed against SNPs
IL277921A (en) RNA new small operators
IL280581A (en) RNAi variant against alpha-synuclein
IL275903A (en) Antisense oligonucleotides directed against alpha-synculin and their uses
SG10201913477UA (en) G-quadruplex-containing antisense oligonucleotides
IL275902A (en) Antisense oligonucleotides directed against alpha-synculin and their uses
SG10202008771WA (en) Combination therapy with liposomal antisense oligonucleotides
ZA202100244B (en) Combinatorial gene therapy
IL309445A (en) PIKFYVE antisense oligonucleotides
EP3999523A4 (en) MELANOPHILIN ANTISENSE OLIGONUCLEOTIDES
EP3532617A4 (en) ANTISENSE OLIGONUCLEOTID
SG11202008247WA (en) Matrix metalloproteinase-1 antisense oligonucleotides
IL263852B (en) Oligonucleotides containing modified nucleosides
IL286826A (en) angptl2 oligonucleotides and their use
SG11202012829RA (en) Acetyl-coa carboxylase2 antisense oligonucleotides
GB201714330D0 (en) Oligonucleotides
EP3565825A4 (en) SNAP25 ANTISENSE OLIGONUCLEOTID
GB201814450D0 (en) Antisense oligonucleotides